SCHEMBL6800877

SCHEMBL6800877

NC1C2CN(c3cc4c(cc3F)c(=O)n(O)c(=O)n4C3CC3)CC12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.37
PRKD3 O94806 1/20 0.37
PIM1 P11309 1/20 0.37
GSK3A P49840 1/20 0.37
IRAK1 P51617 1/20 0.37
RPS6KA3 P51812 1/20 0.37
DYRK1A Q13627 1/20 0.37
PIM3 Q86V86 1/20 0.37
CSNK1G3 Q9Y6M4 1/20 0.37
EPHA2 P29317 1/20 0.35
FLT4 P35916 1/20 0.35
RARB P10826 1/20 0.35
TBXAS1 P24557 1/20 0.35
SLC6A3 Q01959 1/20 0.35
KDM4E B2RXH2 4/20 0.35
ALDH1A1 P00352 4/20 0.35
LMNA P02545 3/20 0.35
HPGD P15428 3/20 0.35
HSD17B10 Q99714 3/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13713249 1.00 GSK3B (0.37) GSK3BPRKD3PIM1GSK3AIRAK1
SCHEMBL6800873 1.00 GSK3B (0.37) GSK3BPRKD3PIM1GSK3AIRAK1
SCHEMBL6797651 0.91 PRKD3 (0.42) GSK3BPRKD3PIM1GSK3AIRAK1
SCHEMBL13713252 0.85 PIM1 (0.51) GSK3BPRKD3PIM1GSK3AIRAK1
SCHEMBL6800209 0.85 PIM1 (0.51) GSK3BPRKD3PIM1GSK3AIRAK1
SCHEMBL6802382 0.83 LMNA (0.42) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL6802314 0.82 PIM1 (0.38) GSK3BPIM1GSK3APIM3ALDH1A1
SCHEMBL7015316 0.80 GSK3B (0.34) GSK3BPRKD3PIM1GSK3AIRAK1
SCHEMBL6795074 0.80 TOP1 (0.54) GSK3BPRKD3PIM1GSK3AIRAK1
SCHEMBL6802354 0.79 EPHA2 (0.48) GSK3BEPHA2FLT4RARBTBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP claimed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US claimed
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed
EP-1028950-A1 NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 2000-08-23 EP disclosed
WO-1999021840-A1 NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A GSK3B 2231/4885PRKD3 1822/4885PIM1 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.